-
Bevacizumab added to chemotherapy, particularly paclitaxel and cisplatin, was efficacious in all response outcomes (objective response, progression-free survival, and overall survival) without diminution in quality of life or unacceptable toxicity.
-
In a well-controlled retrospective analysis of patients who presented with metastatic colorectal cancer, primary tumor resection was associated with improved overall survival.
-
In a multicenter, randomized, double-blind, placebo-controlled clinical trial of bevacizumab added to standard temozolomide and radiation therapy for patients with glioblastoma multiforme, progression-free survival but not overall survival was enhanced.
-
-
Pick your poison: Hypervirulent KPC, untreatable E. coli in the community
-
For years scarce data on health care associated infections in long term care has been extrapolated from small studies and published reports, but a new era of infection prevention is opening that may eventually produce the kind of benchmarking and national comparative HAI rates used in hospitals.
-
-
-
Of all the motivations to become an infectious disease doctor, this is one of the more unusual paths taken: lose most of one leg and nearly all of your life to a series of recurrent near pan-resistant bacterial infections that you've finally fought into remission but still have a 30% chance of coming back and trying to kill you.
-
